Peptide N-Terminal Acetylation and C-Terminal Amidation: Why Caps Matter

In their native form, peptides have a free amino group (NH2) at the N-terminus and a free carboxyl group (COOH) at the C-terminus. Terminal modifications — also called end-capping — replace these free groups with chemically distinct moieties. The two most common modifications are N-terminal acetylation (Ac-) and C-terminal amidation (-NH2). These modifications are routinely available from peptide synthesis vendors and are among the most frequently requested custom options [1].

Terminal caps serve multiple purposes: they protect peptides from enzymatic degradation, alter the charge state of the molecule, and can influence receptor binding. Understanding when and why to request capped peptides is an important practical consideration for researchers ordering custom synthesis.

N-terminal acetylation replaces the free alpha-amino group with an acetyl group (CH3CO-), forming an amide bond. This modification eliminates the positive charge that would otherwise exist at the N-terminus at physiological pH. The acetyl group is small and typically does not cause steric interference with receptor binding, making it a conservative modification [2].

Acetylation is performed on the resin during SPPS by treating the fully assembled, still-protected peptide with acetic anhydride and a base such as DIEA. The reaction is straightforward and inexpensive, adding minimal cost to synthesis. The acetyl group is stable under standard cleavage and deprotection conditions (TFA cocktails), so it survives the final processing steps intact.

C-terminal amidation replaces the free carboxyl group with a primary amide (CONH2), eliminating the negative charge at the C-terminus at physiological pH. Many naturally occurring bioactive peptides are C-terminally amidated — examples include oxytocin, vasopressin, and GnRH. In these cases, amidation is often required for full biological activity because the amide group participates in receptor binding interactions [3].

In SPPS, C-terminal amidation is achieved by using a Rink amide resin instead of a Wang or 2-chlorotrityl chloride resin. The resin linker determines whether cleavage produces a free acid (COOH) or an amide (CONH2) at the C-terminus. This choice must be made before synthesis begins, as it cannot be easily changed after assembly. Researchers should specify the desired C-terminus when ordering custom peptides.

Exopeptidases are enzymes that cleave amino acids from the ends of peptide chains. Aminopeptidases attack the N-terminus, while carboxypeptidases attack the C-terminus. Free terminal groups serve as recognition elements for these enzymes. By capping both termini, the peptide becomes resistant to exopeptidase degradation, which can significantly extend its half-life in biological media [4].

This is distinct from endopeptidase resistance, which requires modifications at internal cleavage sites (such as D-amino acid substitution). A fully capped peptide (Ac-peptide-NH2) is protected against exopeptidases but remains susceptible to endopeptidases that recognize internal sequences. For maximum proteolytic stability, researchers may combine terminal capping with internal modifications such as D-amino acid substitutions or backbone N-methylation.

Terminal modifications change the net charge of the peptide at physiological pH. An uncapped peptide has a positive charge at the N-terminus (NH3+) and a negative charge at the C-terminus (COO-). Acetylation removes the N-terminal positive charge; amidation removes the C-terminal negative charge. A doubly capped peptide (Ac-peptide-NH2) has a net charge determined solely by its side chains [5].

These charge changes affect solubility, isoelectric point, and aggregation behavior. Removing charges can reduce solubility in aqueous solutions, particularly for hydrophobic peptides that relied on terminal charges for water solubility. Conversely, eliminating charges can reduce non-specific electrostatic interactions with assay surfaces, membranes, or other proteins. Researchers should consider these trade-offs when deciding whether to cap their peptides.

For peptides that mimic naturally amidated sequences (oxytocin, GnRH, calcitonin), C-terminal amidation is essential for maintaining full biological activity. The amide group often forms a hydrogen bond with the receptor that the free carboxyl group cannot replace. Ordering these peptides as free acids will result in reduced or abolished activity [6].

For other peptides, terminal modifications may have minimal effect on receptor binding. The impact depends on whether the terminal residues are part of the receptor-binding pharmacophore. Structure–activity relationship (SAR) data for the specific peptide of interest should guide the decision. When SAR data are unavailable, testing both capped and uncapped versions in parallel is the safest approach to ensure accurate results.

N-terminal acetylation adds negligible cost and time to synthesis. C-terminal amidation requires a different resin but does not otherwise complicate the synthesis process. Both modifications are standard offerings from reputable peptide vendors. The COA should explicitly state whether the peptide is acetylated, amidated, or has free termini [7].

Mass spectrometry confirmation is important for verifying terminal modifications. Acetylation adds 42.04 Da to the expected molecular weight, and amidation subtracts 0.98 Da (replacing OH with NH2). These mass shifts are easily detectable by ESI-MS or MALDI-TOF and should be confirmed against the theoretical mass for the modified sequence. Discrepancies may indicate incomplete modification or unexpected side reactions during synthesis.

Request terminal caps when the peptide will be used in protease-rich environments (serum, tissue homogenates, cell culture), when the natural bioactive form is amidated, when you want to minimize charge-dependent non-specific binding in assays, or when extending peptide stability is important for the experimental timeline [8].

Leave termini uncapped when terminal charges are needed for solubility, when the uncapped form is required to match a published protocol, when you need to conjugate the peptide through the N- or C-terminus (capping blocks conjugation chemistry), or when the free termini are part of the bioactive pharmacophore. If uncertain, discuss the intended application with the synthesis vendor — experienced vendors can recommend the appropriate terminal modification.

N-terminal acetylation and C-terminal amidation protect peptides from exopeptidase degradation. These modifications alter the charge state, which affects solubility and non-specific interactions. Many naturally bioactive peptides require C-terminal amidation for full activity. Terminal caps are inexpensive, standard modifications available from most peptide vendors. Researchers should specify terminal modification preferences when ordering and verify them by mass spectrometry on the COA.